CTLA4: Cytotoxic T-lymphocyte protein 4
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Inhibitory receptor acting as a major negative regulator of T-cell responses.
- Drugs that act on it: 6
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Ipilimumab | Approved | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
| Tremelimumab | Approved | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
| Cadonilimab | — | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
| Erfonrilimab | — | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
| Quavonlimab | — | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
| Zalifrelimab | — | Cytotoxic T-lymphocyte protein 4 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency
- 0.80
- Hashimoto thyroiditis
- 0.68
- Non-small cell lung carcinoma
- 0.61
- Melanoma
- 0.61
- Hypothyroidism
- 0.60
- Graves disease
- 0.59
Drugs and mechanisms are from ChEMBL CHEMBL2364164 (CC BY-SA 3.0). Gene name, function (UniProt P16410, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets